Literature DB >> 33650976

Effectiveness of the Alfalfa App in Warfarin Therapy Management for Patients Undergoing Venous Thrombosis Prevention and Treatment: Cohort Study.

Hua Cao1,2, Shaojun Jiang3,4, Meina Lv3,4, Tingting Wu3,4, Wenjun Chen3,4, Jinhua Zhang3,4.   

Abstract

BACKGROUND: Over the years, the internet has enabled considerable progress in the management of chronic diseases, especially hypertension and diabetes. It also provides novel opportunities in online anticoagulation management. Nevertheless, there is insufficient evidence regarding the effectiveness of online anticoagulation management.
OBJECTIVE: This study explored the effectiveness and safety of warfarin management via the Alfalfa app, so as to provide evidence in support of anticoagulant management through online services.
METHODS: In this retrospective, observational cohort study, 824 patients were included. In the offline group, patients went to the hospital clinic for warfarin management. In the Alfalfa app group, patients reported the dose of warfarin, current international normalized ratio (INR) value, and other related information through the Alfalfa app. Physicians or pharmacists used the app to adjust the dose of warfarin and determined the time for the next blood INR testing. Patients completed INR testing by point-of-care at home or hospital. The primary outcome of the study was the percentage of time in therapeutic range (TTR). Secondary outcomes included minor and major bleeding events, thrombotic events, warfarin-related emergency department visits, hospital admissions, and high INR values.
RESULTS: The TTR and percentage of INR values in the range were significantly higher in the Alfalfa app group than in the offline group (79.35% vs 52.38%, P<.001; 3314/4282, 77.39% vs 2005/4202, 47.72%, P<.001, respectively). Patients managed via the Alfalfa app had lower rates of subtherapeutic (172/4282, 4.02% vs 388/4202, 9.23%; P<.001), supratherapeutic (487/4282, 11.37% vs 882/4202, 20.99%; P<.001), and extreme subtherapeutic INR values (290/4282, 6.77% vs 910/4202, 21.66%; P<.001). Additionally, the Alfalfa app group had lower incidences of major bleeding (2/425, 0.5% vs 12/399, 3.0%; P=.005), warfarin-related emergency department visits (13/425, 3.1% vs 37/399, 9.3%; P<.001), and hospital admissions (1/425, 0.2% vs 12/399, 3.0%; P=.001) compared with the offline group. However, the Alfalfa app group had a higher incidence of minor bleeding than the offline group (45/425, 10.6% vs 20/399, 5.0%; P=.003). There were similar incidences in extreme supratherapeutic INR values (19/4282, 0.44% vs 17/4202, 0.40%; P=.78) and thromboembolic events (1/425, 0.2% vs 1/399, 0.3%; P=.53) between the two groups.
CONCLUSIONS: Warfarin management is superior via the Alfalfa app than via offline services in terms of major bleeding events, warfarin-related emergency department visits, and hospital admissions. ©Hua Cao, Shaojun Jiang, Meina Lv, Tingting Wu, Wenjun Chen, Jinhua Zhang. Originally published in JMIR mHealth and uHealth (http://mhealth.jmir.org), 02.03.2021.

Entities:  

Keywords:  INR; TTR; anticoagulation; app; bleeding; mobile phone; offline; online; smartphone; telemedicine; warfarin

Year:  2021        PMID: 33650976      PMCID: PMC7967226          DOI: 10.2196/23332

Source DB:  PubMed          Journal:  JMIR Mhealth Uhealth        ISSN: 2291-5222            Impact factor:   4.773


  31 in total

1.  Telephone versus office-based management of warfarin: impact on international normalized ratios and outcomes.

Authors:  Laura G Stoudenmire; Christina E DeRemer; Hazem Elewa
Journal:  Int J Hematol       Date:  2014-06-21       Impact factor: 2.490

2.  Outcomes of an online pharmacist-managed anticoagulation clinic for individuals on warfarin therapy living in rural communities.

Authors:  Jinhua Zhang; Maobai Liu; Qiang Chen; Jianmei Wu; Hua Cao
Journal:  Thromb Res       Date:  2017-07-20       Impact factor: 3.944

3.  Clinical and Financial Outcomes Evaluation of Multimodal Pharmacist Warfarin Management of a Statewide Urban and Rural Population.

Authors:  James C Lee; Kathleen E Horner; Michelle L Krummel; Deanna L McDanel
Journal:  J Pharm Pract       Date:  2017-04-26

4.  Comparison of outcomes using 2 delivery models of anticoagulation care.

Authors:  Anthony G Staresinic; Christine A Sorkness; Brian M Goodman; Denise Walbrandt Pigarelli
Journal:  Arch Intern Med       Date:  2006-05-08

Review 5.  Prosthetic Heart Valve Thrombosis.

Authors:  George D Dangas; Jeffrey I Weitz; Gennaro Giustino; Raj Makkar; Roxana Mehran
Journal:  J Am Coll Cardiol       Date:  2016-12-20       Impact factor: 24.094

6.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

7.  Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.

Authors:  Jonas Bjerring Olesen; Gregory Y H Lip; Jesper Lindhardsen; Deirdre A Lane; Ole Ahlehoff; Morten Lock Hansen; Jakob Raunsø; Janne Schurmann Tolstrup; Peter Riis Hansen; Gunnar Hilmar Gislason; Christian Torp-Pedersen
Journal:  Thromb Haemost       Date:  2011-07-20       Impact factor: 5.249

8.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

9.  [The multicenter study on the registration and follow-up of low anticoagulation therapy for the heart valve operation in China].

Authors:  L Dong; Y K Shi; J P Xu; E Y Zhang; J C Liu; Y X Li; Y M Ni; Q Yang; T Han; B Fu; J Chen; L Ren; S L Wei; H Chen; K X Liu; F X Yu; J S Liu; M D Xiao; S M Wu; K L Zhang; H L Huang; S L Jiang; C H Qiao; C S Wang; Z Y Xu; X M Zhou; D J Wang; L X Ni; Y B Xiao; S L Jiang; G M Zhang; G Y Liang; S Y Yang; P Bo; Q J Zhong; J B Zhang; X Zhang; Y B Zhu; X Teng; P Zhu; F Huang; Y M Xiao; G Q Cao; H Tian; L M Xia; F L Lu; Y Q Liu; D X Liu; H Xu; Y Yuan; M Li; C Chang; X C Wu; Z Xu; P Guo; Y J Bai; W B Xue; X Y Jiang; Z H Na; Q Y Zeng; H Cai; Y L Wang; R Xiong; S Jin; X M Zheng; D Wu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2016-05-24

10.  Effect of Gene-Based Warfarin Dosing on Anticoagulation Control and Clinical Events in a Real-World Setting.

Authors:  Jinhua Zhang; Tingting Wu; Wenjun Chen; Jinglan Fu; Xiaotong Xia; Liangwan Chen
Journal:  Front Pharmacol       Date:  2020-01-17       Impact factor: 5.810

View more
  2 in total

1.  Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study.

Authors:  Shaojun Jiang; Meina Lv; Zhiwei Zeng; Zongwei Fang; Mingrong Chen; Jiafen Qian; Tingting Wu; Wenjun Chen; Jinhua Zhang
Journal:  J Thromb Thrombolysis       Date:  2022-01-29       Impact factor: 2.300

Review 2.  Smartphone Apps for Managing Antithrombotic Therapy: Scoping Literature Review.

Authors:  Friederike Praus; Bartosz Krzowski; Tabea Walther; Christian Gratzke; Paweł Balsam; Arkadiusz Miernik; Philippe Fabian Pohlmann
Journal:  JMIR Cardio       Date:  2022-06-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.